HEALACE GEL

Indications

• Allergic rhinitis (hay fever)
• Urticaria (hives)
• Allergic conjunctivitis
• Other allergic skin conditions

Dosage

Children: Refer to the BNF for Children for specific dosing guidelines.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

Chlorpheniramine is a first-generation antihistamine that acts as a selective antagonist of the H1 histamine receptor. By binding to these receptors, it prevents histamine from exerting its effects, thus alleviating symptoms such as itching, sneezing, and runny nose. Additionally, chlorpheniramine may have some anticholinergic effects, which can contribute to its efficacy in reducing secretions.

Pharmacodynamics

The pharmacodynamic effects of chlorpheniramine include sedation and reduction of allergic symptoms. It crosses the blood-brain barrier, leading to central nervous system effects, which can result in drowsiness. The onset of action typically occurs within 1 hour of administration, and its effects can last for several hours.

Pharmacokinetics

Chlorpheniramine is well-absorbed from the gastrointestinal tract, with peak plasma concentrations occurring approximately 2 to 6 hours after oral administration. It has a volume of distribution of around 3-5 L/kg, and it is extensively metabolized in the liver, primarily via the cytochrome P450 system. The elimination half-life is typically between 12 to 15 hours, allowing for once or twice daily dosing in most cases. The drug and its metabolites are excreted primarily in urine.

Pregnancy

The safety of derived products during pregnancy has not been established. Use only if the potential benefits outweigh the risks.

Breast-feeding

Caution is advised when administering derived products during breastfeeding, as it is not known whether they are excreted in human milk.

Storage

Store in a cool, dry place, away from direct sunlight and moisture.

Indications

• Growth hormone deficiency
• Turner syndrome
• Chronic kidney disease
• Prader-Willi syndrome
• Idiopathic short stature

Dosage

Children: Refer to established clinical guidelines, as specific dosing may vary based on condition and patient specifics.

Adults: Refer to established clinical guidelines, as specific dosing may vary based on condition and patient specifics.

Mechanism of action

Growth hormone stimulates growth and cell reproduction by binding to specific receptors on target tissues, primarily in the liver, muscle, and adipose tissue. This binding activates the JAK2-STAT5 signaling pathway, leading to the production of IGF-1 in the liver, which mediates many of the growth-promoting effects. Additionally, GH promotes lipolysis, increases protein synthesis, and enhances the uptake of amino acids by cells.

Pharmacodynamics

The primary pharmacodynamic effects of growth factors, especially growth hormone, include stimulation of linear growth in children, increased muscle mass, and decreased body fat. IGF-1 contributes to cellular growth and development in various tissues. The overall anabolic effects of growth hormone include enhanced protein metabolism, increased fat utilization, and an increase in the number and size of muscle fibers.

Pharmacokinetics

Growth hormone has a short half-life of approximately 20-30 minutes when administered intravenously, but its effects can last longer due to downstream signaling pathways activated by IGF-1. GH is secreted in a pulsatile manner by the anterior pituitary gland, with levels peaking during sleep. It is metabolized primarily in the liver and kidneys, and its clearance can be affected by factors such as age, body composition, and the presence of certain diseases.

Pregnancy

The effects of growth hormone therapy during pregnancy are not well established. It is generally recommended to avoid use unless absolutely necessary due to potential risks to the fetus.

Breast-feeding

Growth hormone is not expected to be excreted in breast milk, but caution is advised when considering treatment in breastfeeding individuals.

Storage

Growth hormone should be stored in a refrigerator at 2-8 degrees Celsius. Do not freeze. Protect from light.

Dosage

Children: Dosage for human-derived biological products in pediatrics should be determined based on specific product guidelines and the clinical context.

Adults: Dosage for human-derived biological products varies widely. Refer to specific product information for appropriate dosing.

Mechanism of action

Human physiology is governed by complex biological systems involving various cellular and molecular pathways. The mechanisms of action for human-derived biological products vary widely depending on the specific context, including immune response, hormonal regulation, and metabolic processes.

Pharmacodynamics

Pharmacodynamics in humans involves the interaction of drugs with biological systems, resulting in therapeutic effects. This includes receptor binding, signal transduction, and physiological responses. The effects are influenced by genetic factors, existing health conditions, and concurrent medications.

Pharmacokinetics

Pharmacokinetics in humans involves the absorption, distribution, metabolism, and excretion (ADME) of substances. Factors such as age, sex, body weight, and organ function can significantly influence these processes. Drug absorption may occur via oral, intravenous, or other routes, while distribution depends on blood flow and tissue permeability. Metabolism typically occurs in the liver, and excretion primarily takes place through the kidneys.

Pregnancy

There is no specific information available; consult local guidelines.

Breast-feeding

There is no specific information available; consult local guidelines.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Prevention of bleeding in patients with thrombocytopenia
• Management of bleeding disorders
• Support during surgical procedures to minimize blood loss

Dosage

Children: Refer to specific clinical guidelines or a detailed pharmacological reference for appropriate dosing based on the clinical scenario.

Adults: Refer to specific clinical guidelines or a detailed pharmacological reference for appropriate dosing based on the clinical scenario.

Mechanism of action

Platelets are activated by various stimuli, including collagen and thrombin, which lead to a series of intracellular signaling events. This activation results in shape change, granule release, and aggregation. The main pathways involved include the activation of GPIIb/IIIa receptors that facilitate platelet aggregation through fibrinogen binding, and the release of ADP and thromboxane A2 that further promote aggregation and vasoconstriction.

Pharmacodynamics

Platelets have a lifespan of approximately 7-10 days in circulation. Their primary function is to form a stable clot at the site of vascular injury. The interaction of platelets with the endothelium and other platelets is mediated through various receptors and adherent proteins, such as von Willebrand factor. Activation of platelets leads to the release of clotting factors and signaling molecules that enhance thrombus formation and repair of the damaged endothelium.

Pharmacokinetics

Platelets are produced in the bone marrow and released into the bloodstream. Their production is regulated by thrombopoietin, a hormone produced by the liver and kidneys. Upon activation, platelets adhere to the damaged site and form aggregates. They are eventually cleared from circulation by the spleen and liver, primarily through macrophage-mediated phagocytosis. The kinetics of platelet turnover can be influenced by various factors, including diseases affecting bone marrow function, immune responses, and certain medications.

Contra-indications

• Hypersensitivity to platelet components
• Active bleeding disorders
• Severe thrombocytopenia
• Bone marrow disorders affecting platelet production

Adverse effects

• Thrombosis
• Thrombocytopenia
• Hemorrhage
• Allergic reactions
• Fatigue
• Nausea
• Headache

Interactions

• Anticoagulants may increase the risk of bleeding
• Nonsteroidal anti-inflammatory drugs (NSAIDs) can affect platelet function
• Certain antibiotics may influence platelet levels

Precautions

• Monitor platelet counts regularly
• Assess for signs of bleeding
• Use with caution in patients with a history of bleeding disorders
• Consider potential drug interactions

Pregnancy

Platelet transfusions may be indicated in certain obstetric conditions, but their use should be carefully considered.

Breast-feeding

No specific recommendations; however, platelet transfusions are generally considered safe during breastfeeding.

Storage

Platelets should be stored at room temperature (20-24°C) and used within 5 days of collection.

Formulations

• Platelet concentrate
• Apheresis platelets
• Platelet-rich plasma

Indications

• Diabetes mellitus
• Chronic kidney disease-related anemia
• Hemophilia
• Cancer (as targeted therapy)
• Autoimmune diseases (e.g., rheumatoid arthritis)

Dosage

Children: Refer to specific product guidelines for dosing information.

Adults: Refer to specific product guidelines for dosing information.

Mechanism of action

Recombinant drugs function by mimicking the action of naturally occurring proteins in the body. For instance, recombinant insulin binds to insulin receptors on target tissues, facilitating glucose uptake and metabolism. Erythropoietin stimulates erythropoiesis by binding to erythropoietin receptors in the bone marrow, promoting the production of red blood cells.

Pharmacodynamics

The pharmacodynamics of recombinant drugs vary depending on the specific protein or hormone being replaced or supplemented. Generally, they exert their effects at the cellular level by interacting with specific receptors, leading to a cascade of biological responses. The therapeutic effects are usually dose-dependent and can vary based on the patient's biological response and the presence of antibodies against the recombinant product.

Pharmacokinetics

Pharmacokinetics of recombinant drugs include absorption, distribution, metabolism, and excretion (ADME) characteristics that can differ significantly based on the specific drug. Many recombinant proteins have a short half-life and require parenteral administration. They are typically distributed throughout the body via the bloodstream, metabolized by the liver and other tissues, and excreted primarily through the kidneys. The pharmacokinetics may be influenced by the patient's age, weight, and overall health.

Pregnancy

Recombinant proteins should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when administering recombinant proteins during breastfeeding, as the effects on the infant are not well established.

Storage

Store in a refrigerator at 2-8 degrees Celsius. Do not freeze, and protect from light.